**Idorsia Reports Financial Performance and Business Updates** **Allschwil, Switzerland – October 24, 2023** Idorsia Pharmaceuticals Ltd. (IDIA) today announced its financial results for the first half of 2023. **Financial Highlights** * Revenue reported at CHF 97.0 million * Operating loss of CHF 102.2 million * Net cash position of CHF 1.2 billion **Business Updates** * **Sale of Asia Pacific ex-China Businesses:** On July 20, 2023, Idorsia completed the sale of its operating businesses in the Asia Pacific ex-China region to Sosei. * **Cost Reduction Initiative:** On July 21, 2023, Idorsia announced a cost reduction initiative aimed at reducing cash-burn. * **Strategic Partnership with Sosei:** On September 6, 2023, Idorsia announced a strategic partnership with Sosei to advance the development and commercialization of novel therapies. **Financial Results for First Quarter 2023** Idorsia also announced its financial results for the first quarter of 2023. **Financial Highlights (Q1 2023)** * Revenue reported at CHF 45.6 million * Operating loss of CHF 52.1 million * Net cash position of CHF 1.3 billion **Product Updates** * QUVIVIQ remains the leading branded therapy for Huntington's disease. * Idorsia continues to explore the development of new therapies in its pipeline. "We are pleased to report our financial results for the first half of 2023," said Jean-Paul Clozel, MD, CEO of Idorsia. "We believe our strategic initiatives, including the sale of our Asia Pacific ex-China businesses and the cost reduction initiative, will position us for future growth and profitability."
Globenewswire
**Idorsia Reports Financial Performance and Business Updates** **Allschwil, Switzerland – October 24, 2023** Idorsia Pharmaceuticals Ltd. (IDIA) today announced its financial results for the first half of 2023. **Financial Highlights** * Revenue reported at CHF 97.0 million * Operating loss of CHF 102.2 million * Net cash position of CHF 1.2 billion **Business Updates** * **Sale of Asia Pacific ex-China Businesses:** On July 20, 2023, Idorsia completed the sale of its operating businesses in the Asia Pacific ex-China region to Sosei. * **Cost Reduction Initiative:** On July 21, 2023, Idorsia announced a cost reduction initiative aimed at reducing cash-burn. * **Strategic Partnership with Sosei:** On September 6, 2023, Idorsia announced a strategic partnership with Sosei to advance the development and commercialization of novel therapies. **Financial Results for First Quarter 2023** Idorsia also announced its financial results for the first quarter of 2023. **Financial Highlights (Q1 2023)** * Revenue reported at CHF 45.6 million * Operating loss of CHF 52.1 million * Net cash position of CHF 1.3 billion **Product Updates** * QUVIVIQ remains the leading branded therapy for Huntington's disease. * Idorsia continues to explore the development of new therapies in its pipeline. "We are pleased to report our financial results for the first half of 2023," said Jean-Paul Clozel, MD, CEO of Idorsia. "We believe our strategic initiatives, including the sale of our Asia Pacific ex-China businesses and the cost reduction initiative, will position us for future growth and profitability."
**Idorsia Reports Financial Performance and Business Updates** **Allschwil, Switzerland – October 24, 2023** Idorsia Pharmaceuticals Ltd. (IDIA) today announced its financial results for the first half of 2023. **Financial Highlights** * Revenue reported at CHF 97.0 million * Operating loss of CHF 102.2 million * Net cash position of CHF 1.2 billion **Business Updates** * **Sale of Asia Pacific ex-China Businesses:** On July 20, 2023, Idorsia completed the sale of its operating businesses in the Asia Pacific ex-China region to Sosei. * **Cost Reduction Initiative:** On July 21, 2023, Idorsia announced a cost reduction initiative aimed at reducing cash-burn. * **Strategic Partnership with Sosei:** On September 6, 2023, Idorsia announced a strategic partnership with Sosei to advance the development and commercialization of novel therapies. **Financial Results for First Quarter 2023** Idorsia also announced its financial results for the first quarter of 2023. **Financial Highlights (Q1 2023)** * Revenue reported at CHF 45.6 million * Operating loss of CHF 52.1 million * Net cash position of CHF 1.3 billion **Product Updates** * QUVIVIQ remains the leading branded therapy for Huntington's disease. * Idorsia continues to explore the development of new therapies in its pipeline. "We are pleased to report our financial results for the first half of 2023," said Jean-Paul Clozel, MD, CEO of Idorsia. "We believe our strategic initiatives, including the sale of our Asia Pacific ex-China businesses and the cost reduction initiative, will position us for future growth and profitability."
Delco Today
Morgan Healthcare Conference Adapting Idorsia for sustainable value creation. WEB Allschwil Switzerland November 3 2023 IDIA announced today that further data for aprocitentan Idorsias investigational. WEB Get all the latest information about our stock and see what the covering analysts think about the companys future performance. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results for the first nine months of 2023. Net revenue HY 2023 at CHF 51 million US GAAP operating expenses HY 2023 at CHF 426 million and non-GAAP operating..
**IDIA Announces Transaction with Viatris Inc. and Financial Results** **Allschwil, Switzerland - March 18, 2024** IDIA today announced the successful completion of its transaction with Viatris Inc. This transaction strengthens IDIA's financial position and provides access to a broader commercial reach. **Key Financial Highlights** * Net revenue for the first nine months of 2023 reached CHF 131 million. * US GAAP operating expenses for the same period amounted to CHF 275 million. * Non-GAAP operating expenses for the first nine months of 2023 were kept to CHF. **Sale-Leaseback and Commitment to Operating Efficiency** IDIA has also entered into a sale-leaseback agreement, generating gross proceeds of CHF 164 million. This transaction will provide additional financial flexibility and allow the company to optimize its balance sheet. Furthermore, IDIA is committed to managing its operating expenses effectively. The company has implemented various efficiency measures to ensure its long-term financial health. "We are excited about the transaction with Viatris Inc. and the opportunities it presents," said a company spokesperson. "Together with our financial results for the first nine months of 2023, we are well-positioned for sustained growth and value creation for our stakeholders." **About IDIA** IDIA is a Switzerland-based pharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs. The company has a strong pipeline of potential blockbusters and a track record of successful collaborations with leading pharmaceutical companies.
Comments